The massive 179% dilution at a 26% discount will likely pressure the stock price further. Existing shareholders face severe dilution; watch for potential additional offerings or pipeline catalysts. The company now has runway through at least April 2027, but clinical-stage risk remains high.
Price Chart
Executive Summary
Rein Therapeutics is selling 50,000,000 shares (2.8x current outstanding) at $1.00 per share, a 26% discount to the last closing price of $1.355, to raise approximately $46.1 million in net proceeds. The offering provides critical capital to a clinical-stage biopharma with a going concern warning, but existing shareholders face massive immediate dilution.
Key Facts
- Selling 50M shares at $1.00, a 26% discount to the prior close of $1.355.
- Shares outstanding will increase from ~28M to ~78M (179% dilution).
- Net proceeds of ~$46.1M after underwriting discounts and estimated expenses.
- Company had only $3.2M cash and a working capital deficit of $1.9M as of Dec 31, 2025.
- Audited financials include a going concern qualification.
- Proceeds will fund working capital and repay $5.375M of promissory notes.
- Underwriters have a 45-day option to purchase an additional 7.5M shares.
Financial Impact
$50M gross proceeds at $1.00/share, 26% discount to last close; shares outstanding increase from 28M to 78M (179% dilution).
Risk Factors
- Massive dilution to existing shareholders from 179% increase in share count.
- Clinical-stage company with no revenue, substantial operating losses, and a going concern warning.
- Need for additional financing beyond this offering to fully execute business plan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-202429 |
| Document: 0001193125-26-202429-index-headers.html | 0001193125-26-202429 |
| Document: 0001193125-26-202429-index.html | 0001193125-26-202429 |
| Document: 0001193125-26-202429.txt | 0001193125-26-202429 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.7042 (−20.80%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.7042 (−12.63%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.7042 (−21.30%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.7042 (−25.77%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.7042 (+30.96%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.7042 (+30.96%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.7042 (+31.63%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 28, 2026 26w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.7042 (−44.77%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.7042 (−52.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers